News Release
Bayer Group

News Overview

May 2, 2012
Not intended for U.S. and UK media:
Bayer’s Xarelto® (Rivaroxaban) Submitted to U.S. FDA for the Treatment of Venous Thromboembolism (VTE) and Long-Term Prevention of Recurrent VTE
» more
April 27, 2012
Management Board Chairman Dr. Marijn Dekkers at the Annual Stockholders’ Meeting of Bayer AG:
Bayer has great potential for the future too
» more
April 26, 2012
1st quarter of 2012:
Encouraging start to the year for Bayer
» more
April 25, 2012
Not intended for US or UK use - Aesthetic medicine:
Positive results from two European Phase III trials with ATX-101 demonstrate reduction of submental fat
» more
April 20, 2012
New fungicidal seed treatment product for oilseed rape:
First approval worldwide for EverGol™ in seed treatment
» more
April 17, 2012
Not intended for U.S. and UK Media: Prevention of Venous Blood Clots after Elective Total Hip or Knee Replacement Surgery:
Real-World Experience Reaffirms Bayer’s Xarelto® (Rivaroxaban) as Safe and Effective in Protecting Patients Against Blood Clots
» more
April 12, 2012
Innovative breeding approach creates new opportunities for sugar beet growers:
Bayer CropScience and KWS SAAT AG co-develop herbicide-tolerant sugar beet
» more
April 12, 2012
Not intended for U.S. and UK media
Bayer’s Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for the Treatment of Pulmonary Embolism (PE) and Prevention of Recurrent Deep Vein Thrombosis (DVT) and PE
» more
April 3, 2012
Not intended for U.S. and U.K. Media
Phase III Trial of Regorafenib in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Meets Primary Endpoint of Improving Progression-Free Survival
» more
March 26, 2012
Not intended for U.S. and UK Media - Treatment of Pulmonary Embolism (PE):
Bayer’s Xarelto® (Rivaroxaban) Proven Effective in Treating Patients with Pulmonary Embolism and in Preventing Recurrent Venous Blood Clots in Phase III EINSTEIN-PE Study
» more
March 19, 2012
Not intended for UK and US Media: Treatment of Pulmonary Embolism (PE):
Results of the Phase III EINSTEIN-PE Study with Bayer’s Xarelto® (Rivaroxaban) to be Presented in Late-Breaking Clinical Trials Session at ACC 2012
» more
March 14, 2012
“Meet Management” investor conference:
Bayer sets ambitious targets for 2014
» more
March 8, 2012
Not intended for U.S. and UK Media
EYLEA® (aflibercept) Injection approved for the Treatment of Wet Age-Related Macular Degeneration in Australia
» more
February 28, 2012
Financial and innovation targets for 2011 achieved
Bayer: sales and EBIT at record levels
» more
8:05 min.
February 28, 2012
Not intended for U.S. and UK Media: Secondary Prevention of Acute Coronary Syndrome (ACS):
Bayer’s Xarelto® (Rivaroxaban) Granted Priority Review by US FDA to Prevent Secondary Cardiovascular Events in Patients with ACS
» more
Werner Wenning
February 23, 2012
Elections to the Supervisory Board to be held at the Annual Stockholders’ Meeting on April 27, 2012
Werner Wenning to be proposed as Chairman of the Supervisory Board of Bayer AG
» more
February 23, 2012
Bayer plans dividend increase for 2011 to EUR 1.65 per share
» more
February 20, 2012
Not intended for U.S. and UK Media
Positive One Year results From Phase 3 Study in Central Retinal Vein Occlusion of VEGF Trap-Eye
» more
January 18, 2012
Not intended for UK and US Media - Stroke Prevention in Patients with Atrial Fibrillation:
Bayer’s Xarelto® Approved in Japan for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
» more
January 18, 2012
Not intended for U.S. and UK Media (LBA #385) - Results of pivotal Phase III study in patients with metastatic colorectal cancer:
Positive Phase III Data on Bayer’s Investigational Drug Regorafenib Show Significant Increase in Overall Survival
» more
more News
http://www.bayer.com/en/news-list-bayer-group.aspx

Copyright © Bayer AG

Special Interest

Print page

Search

Search
Press Newsletter
Last updated: May 2, 2012
Copyright © Bayer AG
×